ARQT News and Press, Arcutis Biotherapeutics Inc. From 05/12/20

Multiple important Phase 3 and Phase 2 data events anticipated during 2020/2021 Arcutis currently expects no impact to its previously disclosed clinical timelines due to COVID-19 Strong financial position with $249.3 million in cash, cash equivalents and marketable securities WESTLAKE...

Enrollment is underway in a Phase 1/2b clinical trial evaluating Arcutis Biotherapeutics ( ARQT -2.4% ) ARQ-252 in adult patients with eczema (atopic dermatitis) on their hands. More news on: Arcutis Biotherapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more...

ARQ-252 is a Potent Topical Small Molecule Inhibitor of JAK1 High Selectivity for JAK1 over JAK2 JAK Inhibition a Biologically Validated Target for Treatment of Hand Eczema WESTLAKE VILLAGE, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a l...

WESTLAKE VILLAGE, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-derma...

FDA requests study amendment to allow inclusion of children ages 2 to 11 years in the DERMIS-1 and DERMIS-2 trials Strong safety profile supported population expansion in pivotal Phase 3 trials Topical Roflumilast potential “Best in Class” topical PDE4 inhibitor Phase 3 t...

Assuming no COVID-19 cancellations, here is a list of noteworthy events during the week of March 15 - 21 for healthcare investors: More news on: Eton Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Arcutis Biotherapeutics, Inc., Healthcare stocks news, , Read more ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

WESTLAKE VILLAGE, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermat...